Last reviewed · How we verify

BHV3241, verdiperstat — Competitive Intelligence Brief

BHV3241, verdiperstat (BHV3241, verdiperstat) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NADPH oxidase 2 inhibitor. Area: Neurology.

phase 2 NADPH oxidase 2 inhibitor NOX2 Neurology Small molecule Live · refreshed every 30 min

Target snapshot

BHV3241, verdiperstat (BHV3241, verdiperstat) — Biohaven Pharmaceuticals, Inc.. BHV3241, also known as verdiperstat, is a small molecule inhibitor of the enzyme NADPH oxidase 2 (NOX2).

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
BHV3241, verdiperstat TARGET BHV3241, verdiperstat Biohaven Pharmaceuticals, Inc. phase 2 NADPH oxidase 2 inhibitor NOX2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NADPH oxidase 2 inhibitor class)

  1. Biohaven Pharmaceuticals, Inc. · 1 drug in this class
  2. Celtaxsys, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BHV3241, verdiperstat — Competitive Intelligence Brief. https://druglandscape.com/ci/bhv3241-verdiperstat. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: